Charles Schwab Investment Management Inc Arcutis Biotherapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 965,066 shares of ARQT stock, worth $24 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
965,066
Previous 860,768
12.12%
Holding current value
$24 Million
Previous $13.5 Million
0.51%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ARQT
# of Institutions
247Shares Held
132MCall Options Held
407KPut Options Held
216K-
Jennison Associates LLC12.3MShares$305 Million0.14% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.5MShares$287 Million5.56% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$268 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$246 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$215 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...